Longer duration of imaging-based progression-free survival seen in intent-to-treat population and those with BRCA<\/em> mutation<\/p>\n<\/h3>\n By Elana Gotkine HealthDay Reporter<\/b><\/p>\n <\/b><\/p>\n FRIDAY, Feb. 17, 2023 (HealthDay News) — For patients with metastatic castration-resistant prostate cancer, treatment with rucaparib is associated with significantly longer duration of imaging-based progression-free survival compared with a control medication, according to a study published online Feb. 16 in the New England Journal of Medicine <\/em>to coincide with the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 16 to 18 in San Francisco.<\/p>\n Karim Fizazi, M.D., Ph.D., from Paris-Saclay University, and colleagues enrolled patients with metastatic, castration-resistant prostate cancer with a BRCA1<\/em>, BRCA2<\/em>, or ATM<\/em> mutation and disease progression after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI). Patients were randomly assigned to receive oral rucaparib or a physician’s choice control (docetaxel or a second-generation ARPI; 270 and 135 patients, respectively [intention-to-treat population]). Overall, 201 and 101 patients, respectively, had a BRCA<\/em> mutation.<\/p>\n The researchers found that the duration of imaging-based progression-free survival was significantly longer in the rucaparib versus control group at 62 months, both in the BRCA<\/em> mutation group (median, 11.2 and 6.4 months, respectively; hazard ratio, 0.50) and in the intention-to-treat group (median, 10.2 versus 6.4 months; hazard ratio, 0.61). The median duration of imaging-based progression-free survival did not differ significantly in the rucaparib and control groups in an exploratory analysis in the ATM<\/em> subgroup (8.1 and 6.8 months, respectively). Fatigue and nausea were the most common adverse events reported with rucaparib.<\/p>\n “The benefit with respect to imaging-based progression-free survival in the rucaparib group was reported both in the BRCA<\/em> subgroup and in the intention-to-treat population, with the greatest benefit in the BRCA<\/em> subgroup,” the authors write.<\/p>\n The study was funded by Clovis Oncology, the manufacturer of rucaparib.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n